- Home
- ALT vs XOMA Comparison
ALT vs XOMA Comparison
Compare ALT & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALT
- XOMA
- Stock Information
- Founded
- ALT 1997
- XOMA 1981
- Country
- ALT United States
- XOMA United States
- Employees
- ALT N/A
- XOMA N/A
- Industry
- ALT Biotechnology: Pharmaceutical Preparations
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- ALT Health Care
- XOMA Health Care
- Exchange
- ALT Nasdaq
- XOMA Nasdaq
- Market Cap
- ALT 292.0M
- XOMA 330.2M
- IPO Year
- ALT N/A
- XOMA N/A
- Fundamental
- Price
- ALT $3.83
- XOMA $32.47
- Analyst Decision
- ALT Strong Buy
- XOMA Strong Buy
- Analyst Count
- ALT 6
- XOMA 2
- Target Price
- ALT $17.40
- XOMA $69.50
- AVG Volume (30 Days)
- ALT 3.0M
- XOMA 57.0K
- Earning Date
- ALT 08-12-2025
- XOMA 08-13-2025
- Dividend Yield
- ALT N/A
- XOMA N/A
- EPS Growth
- ALT N/A
- XOMA N/A
- EPS
- ALT N/A
- XOMA N/A
- Revenue
- ALT $20,000.00
- XOMA $44,952,000.00
- Revenue This Year
- ALT N/A
- XOMA $82.30
- Revenue Next Year
- ALT $761,880.20
- XOMA $12.59
- P/E Ratio
- ALT N/A
- XOMA N/A
- Revenue Growth
- ALT N/A
- XOMA 194.98
- 52 Week Low
- ALT $2.90
- XOMA $18.35
- 52 Week High
- ALT $11.16
- XOMA $35.23
- Technical
- Relative Strength Index (RSI)
- ALT 51.79
- XOMA 61.79
- Support Level
- ALT $3.35
- XOMA $32.60
- Resistance Level
- ALT $3.66
- XOMA $34.60
- Average True Range (ATR)
- ALT 0.19
- XOMA 1.82
- MACD
- ALT 0.07
- XOMA 0.09
- Stochastic Oscillator
- ALT 86.18
- XOMA 66.75
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.